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INTRODUCTION 
Vitiligo is a pigmentary disorder of universal distribution and unknown 
etiology with various precipitating factors. Vitiligo is asymptomatic and benign 
in terms of human life, of uncertain prognosis and fatal from the aesthetic point 
of view. It modifies the conduct of the patients, and quite frequently affects the 
family dynamics. 
Throughout history this has lead to sustained research on its etiology 
and to the search for a medication that will effectively induce repigmentation 
without undesirable side effects. 
At present the various therapeutic options include topical and systemic 
photochemotherapy with psoralens, topical and systemic steroids and 
immunomodulators. Off late topical tacrolimus and narrow band UVB therapy 
is gaining importance. Apart from medical therapies various surgical and 
cosmetic procedures are being carried out in patients with stable vitiligo. 
Since far back in time, numerous drugs for topical and systemic therapy 
have been used for vitiligo, many only with a placebo effect, which in their 
times were considered a panacea for the treatment of vitiligo. Time itself has 
served to discard them, be it for their inefficacy or for the higher incidence of 
side effects. 
Hence there is a need to find an alternative therapy that will offer the 
patient an option for improvement or cure, avoiding these side effects. 
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Melagenina is one such biological product, manufactured in Placental 
Histotherapy Center, Havana, Cuba since 1973. The center claims the 
repigmentation rate of 80-84%, 2 years after starting treatment with 
Melagenina, without local and systemic side effects. It was also claimed that 
addition of calcium chloride to Melagenina enhances its potency and it was 
marketed under the name Melagenina plus lotion. This product was available in 
India since 2003. This product was tested in various other countries with 
encouraging results. The aim of our study is to find the efficacy of Melagenina 
plus lotion in patients with localized stable vitiligo, when used alone and in 
combination with UVA in our Indian population. 
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REVIEW OF LITERATURE 
VITILIGO: 
Vitiligo is a common, specific, usually progressive, melanocytopenic, 
often heritable, acquired disorder characterized by well circumscribed milky 
white cutaneous macules and patches, affecting skin and mucous membranes. 
Historical Aspects: 
The term Vitiligo was first used by the Roman physician Celsus in his 
Latin medical classic De Medicina in 30 AD. 
According to Bateman ‘the white and glistening appearance, bearing 
some resemblance to the pale pink flesh of calves (vituli) seems to have given 
rise to the generic term vitiligo. El Mofty suggests that vitiligo is derived from 
the Latin word ‘Vitelius’ which means ‘calf’ referring to the characteristic 
white patches of the disease resembling the white patches of a spotted calf.1 
Other authors however believe that the term is derived from the Latin word 
‘vitium’ meaning a fault or blemish.2 
It is interesting to note that the Rigveda (6000 BC or earlier) named 
leukoderma as ‘kilas’, meaning a white spotted deer.The earliest reference to 
the disease is in 2200 BC in the ancient literature of Iran, ‘Tarkh-e-Tibbl-e-
Iran’.  The oldest information concerning vitiligo comes from the ‘Ebers 
Papyrus’ writings about Pluraonic medicine in 1550 BC.3 
In 1400 BC leukoderma has been mentioned as a variety of leprosy 
(Swetha Kustha) and several herbal remedies have been mentioned in the 
  
4
Ancient Indian sacred book, ‘Atharva Veda’.4 These remedies highlighted the 
value of Vasuchika which was much later identified with the plant Psoralia 
corylifolia, oil from the seeds (bouchi seeds) contain active furocoumarin.5 A 
similar drug, ‘pu-ku-c’ for treating leukoderma has been mentioned in the 
ancient Chinese literature. 
Much later in the 13th century, Ibn Eb Bitar in Egypt mentioned the cure 
of leukoderma by an Egyptian herb known as Ammi Majus, from the fruit 
extract of which important furocoumarins were eventually identified in the 20th 
century.6 
In Amarkosha the term svitra has been used synonymously with 
‘padosphota’ meaning ‘flower of legs’, ‘twakpuspi’, meaning ‘flower of skin’, 
and ‘sishmati’, which means ‘spreading whiteness’.In Vinayak Pitak (624-544 
BC) the sacred book of Buddhism, there is mention of a disease associated with 
white spots and persons so suffering were not eligible for ordainment. A 
disease suggestive of vitiligo finds mention in the writings of Greek historian 
Herodotus (484-425 BC) .7 In ancient Arabic books, ‘white skin’ was expressed 
as ‘baras’. The word baras is mentioned in the Koran Ch 3 v 48 and Ch 5 v 
109. 
The white spots were also described in the Old Testament under the 
Hebra word ‘Zora at’, and this word was translated as ‘lepra’ in the Greek and 
English translations of the Bible.7 
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Stigma attached to Vitiligo: 
The Stigma associated with vitiligo dates back to ancient times and 
continues to date in some culture. In ancient times Vitiligo was considered as a 
God’s punishment for sins. 
…....The priest shall put him in isolation for seven days … (Leviticus 
1405 BC) 
……Man and women suffering from this disease (white spot) are not 
eligible for ordainment (Vinayak Pitak 624-544 BC) 
…….He must have sinned against the sun’ and often the sufferers were 
shunned by their society…..Must be forced to leave the country (Herodotus 
484-425 BC) 
…….A person who had stolen clothes in his former existence may 
suffer from ‘svitra’ (Manusmruti 200BC) 
Pandemics of leprosy in the middle ages as well as abundant myths 
particularly in underdeveloped countries, cast the ‘unclean spell of leprosy; on 
those with vitiligo.8 In South India, vitiligo is still called ‘Ven Kushtam’ 
translated as ‘white leprosy’. As the social stigma makes patient conceal their 
white spots, even today in the Indian Villages, the disease is often called 
‘Charak’ meaning ‘the secret disease’. 
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EPIDEMIOLOGY 
Vitiligo is relatively common disorder affecting all races across the 
globe.9 Both sexes are equally affected.10 The female prevalence in some 
studies probably attributed to greater concern about a cosmetic defect.11 
The Incidence ranges from 0.14 to 8.8% across the globe.12 The highest 
incidence has been recorded in India and Mexico. The Incidence is roughly 
estimated to be between 3-4% in India13. In India highest Incidence has been 
reported from the states of Gujarat and Rajasthan14. Vitiligo appears to be 
observed more commonly in sun-exposed areas and in darker skin types. 
Vitiligo may develop at any age. Onset has been reported from birth to 
81 years of age. Congenital vitiligo is however very rare.15 The peak age of 
onset in all series was between 10 and 30 years. In 50% of cases the Onset is 
before 20 years of life. 
AETIOPATHOGENESIS 
Although vitiligo is generally recognized as a single entity, the etiology 
is complex. There appears to be a certain genetic predisposition and a number 
of potential precipitating causes. 
GENETIC FACTORS and INHERITANCE 
A positive family history has been observed in 30-40% of vitiligo 
patients suggesting a genetic basis for this disorder.16 Monozygotic twins have 
been seen to have vitiligo with a similar or dissimilar mode of onset, type, 
extent and course of the disease.17 
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It is likely that vitiligo is not transmitted in a simple Mendelian 
autosomal dominant or recessive pattern. The transmission is more complex, 
polygenic with variable expression. No definite human leukocyte antigen 
(HLA) association is established for vitiligo although increased incidence of 
HLA DR4 in black people, HLA B13 in Morocean Jews and HLA BW35 in 
Yemenite Jews with vitiligo have been reported. 
An association between the Catalase gene (CAT) and vitiligo has been 
suggested.18 A novel gene named VITI, possibly associated with vitiligo, has 
been identified recently by differential display. 
Increased incidences of Diabetes mellitus, thyroid diseases and atopic 
diathesis in the family members have been reported. 
Although no definite precipitating factor is ascertained, many factors 
have been incriminated which include local trauma, itching, friction, infections, 
infestations, gastrointestinal disturbances, emotional upset, pregnancy, 
parturition and surgery. However no precipitating factors can be identified in 
50% of cases. 
THEORIES ON THE PATHOGENESIS: 
Theories on the pathogenesis of vitiligo centered on mechanisms for the 
destruction of melanocytes as there are no melanocytes present in the fully 
evolved white macules. Traditionally there have been three hypothesis to 
explain vitiligo.19 
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1. Neural Hypothesis 
2. Self destructive Theory 
3. Autoimmune Theory 
1. NEURAL HYPHOTHESIS 20, 21 
Evidences in favour of neural hypothesis include 
A. Stress and severe emotional trauma is a known initiating or precipitating 
factor in vitiligo. 
B. The common embryologic origin of melanocytes and the nervous 
system. 
C. Dermatomal distribution of segmental vitiligo. 
D. Demonstration of direct contact between cutaneous free nerve endings 
and epidermal melanocytes in vitiligo macules. 
E. Demonstration of neuropeptides in the skin and their ability to regulate 
melanocyte differentiation has given more strength to this hypothesis. 
F. An increased immunoreactivity of neuropeptide (NYP) or an altered 
balance of nerve growth factor receptors and calcitonin gene related 
peptide has been observed in vitiligo. 
G. Alteration of the catecholamine pathway, increased catechol-o-ethyl 
transferase and monoamine oxidase activities and increased expression 
of B2-adrenoreceptors has been described in vitiligo. 
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These alterations are said to induce melanocyte dysfunction and 
melanocyte injury by promoting the production of melanocytotoxic 
compounds and by decreasing the natural detoxification. 
At present, however, the role of nervous system in vitiligo, if any, is 
poorly understood. 
2. SELF DESTRUCTIVE THEORY by A.B.LERNER  22 
Lerner put forth that melanocytes in vitiligo have lost an intrinsic 
protective mechanism that eliminates toxic intermediates or metabolites in 
the melanogenesis pathway. 
This theory stems from the belief that cytotoxic precursors to 
melanin synthesis accumulate and result in the death of melanocytes. 
Melanocytes synthesize melanin by oxidation of tyrosine to 
dihydroxyphenylalanine (DOPA) and to dopaquinone, which by a multistep 
reaction forms indoles. All the intermediates in the biosynthesis of melanin 
are phenols: excessive production or accumulation of phenolic radicals or 
intermediates within the melanocyte could damage the cell.23 
It is well known that workers in rubber and plastic industries who are 
exposed to large quantities of phenols and catechols can acquire 
depigmentation that resembles vitiligo. 
It has been suggested that melatonin receptor and melatonin could 
play a key role in vitiligo. Melatonin is known to stimulate the melanogenic 
pathway without the production of melanins, leading to an accumulation of 
  
10
toxic intermediates which causes injury to keratinocytes and melanocytes 
with release of specific cellular proteins that initiate a secondary 
autoimmune reaction. 
The presence of high levels of Hydrogen peroxide (H2O2) and low 
levels of catalase24 in epidermis of vitiligenous skin suggests that there is an 
increased oxidative stress in vitiligo patients.25 Several pathways could be 
involved in overproduction of H2O2 in vitiligo. 
A. An abnormality in tetrabiopterin metabolism leading to over production 
of metabolites in this pathway, 6BH4 and 7BH4. The defective recycling 
of 6BH4 lead to formation of H2O2.26 
B. Over production of H2O2 is claimed to result also from increased 
catecholamine biosynthesis in association with increased levels of 
monoamine oxidase A from inhibition of thioredoxin / thioredoxin 
reductase by calcium and increased nitric oxide synthase activities. 
3. AUTOIMMUNE THEORY 27 
The association of vitiligo with autoimmune diseases suggested an 
immunologic basis for vitiligo. 
A. Humoral immunity 
1. There is an increased frequency of organ-specific auto antibodies in 
patients with vitiligo, even in the absence of any associated disease 
in up to 30% of patients. Antibodies to thyroid tissue, gastric parietal 
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cell, adrenal cytoplasm and pancreatic islet cell have been 
demonstrated.  
2. Circulating antibodies to various melanocyte antigens, including 
tyrosinase, tyrosinase-related protein 1 and protein 2 have been 
demonstrated. 
3. More recently, autoantibodies to a transcription factor called SOX10 
have been found in vitiligo associated with APECED. 
B. Cell mediated immunity 
Evidence for the role of cellular immunity is even stronger. In marginal 
skin from progressive lesions of generalized and inflammatory vitiligo, an 
infiltrate of skin-homing (CLA+) cytotoxic T cells expressing 
granzyme/perforin is often found close to the remaining melanocytes. This 
infiltrate is composed of CD8 T cells, CD4 T cells and subsets of macrophages, 
and this correlates with the increased number of CLA+ MART-1 reactive CD8 
T cells in the peripheral blood of patients with progressive vitiligo. These 
specific cytotoxic T cells react against the melanocyte differentiating antigens 
in vitiligo patients.28 
It is not known whether these specific immune abnormalities are a cause 
or an effect of the disease, whether they damage melanocytes or aggravate 
melanocyte injury initiated by other causes, or are an irrelevant 
epiphenomenon. 
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4. OTHER HYPOTHETICAL THEORIES 
A. Convergence theory suggests that genetic factors, stress, accumulation 
of toxic compounds, infection, autoimmunity, mutations, altered cellular 
environment, and impaired melanocyte migration and proliferation can 
all contribute to this disease.29 
B. An intrinsic defect of the structure and function of rough endoplasmic 
reticulum in vitiligo Melanocytes.30 
C. deficiency of Melanocyte growth factor 
D. viral origin 
E. dysregulation of Melanocyte apoptosis 
F. Primary disturbance of T lymphocytes resulting in the development of 
“forbidden” clones of autoreactive lymphocytes in the epidermis. 
CLINICAL FEATURES31 
A typical lesion is a well defined depigmented (milky white or chalky) 
macule, round to oval in shape, has slightly brushed to fairly distinct, often 
with scalloped margins, measures from few mm to many cms in diameter, 
showing a variable number of depigmented (white) hairs and without any 
change in the skin texture. 
The number, size, shape, and location of individual macules vary 
widely. Frequently the initial macule occurs on the exposed areas (such as the 
dorsal surface of hands, elbows, feets, legs, knees, neck and face), body folds 
(such as axillae, groin, and sub mammary region in women), lips or genitalia. 
  
13
Of the usually covered areas, the initial lesion is often noted on the chest wall, 
lower back or areola. In general, with extensive involvement the distribution is 
similar to that of hyperpigmentation in Addison’s disease (i.e., exposed areas, 
body folds, periumblical region, mucous membranes, and external orifices, 
sites of recent trauma or pressure or naevi). When lesions occur bilaterally, 
distribution is generally more or less symmetrical. The initial lesion may be 
one or more macules widely varying in size and shape. In some cases almost 
total depigmentation of body surface may develop slowly or rapidly with only a 
few or no islands of normal pigmentation. The lesions enlarge by invading the 
normally pigmented surrounding skin, which assumes a concave shape at the 
border. Virtually no area of skin is exempted. 
Common sites of vitiligo lesions include the extensor surfaces of the 
body such as the pretibial regions, sides of ankles, knees, elbows and skin 
overlying the digits, periorificial areas such as periorbicular & circumoral, 
anogenital areas (glans penis, prepuce, vulva) and also flexor aspect of wrists, 
axillae, groins, lower back, loin, palms, soles, toe and finger tips and scalp. 
Involvement of pretibial region, palms and sole are quite common in India.32  
The initial unifocal lesion may be followed by the appearance of new 
lesions elsewhere. In less than 25% of cases the onset may be multifocal. Onset 
of the lesions is usually insidious. The disease is progressive in nature as a rule 
and course is virtually unpredictable and may be quite erratic, it may be jerky, 
indolent or rapid. While some lesions may show signs of repigmentation, new 
  
14
lesions may develop on other parts of the body simultaneously. There is an 
episodic phase of rapid extension of lesions after remaining quiescent over a 
long period of time. 
Although no definite precipitating factor is ascertained, many factors 
have been incriminated which include local trauma, itching, friction, infection, 
infestations, gastrointestinal disturbances, emotional upset, pregnancy, 
parturition and surgery. However precipitating factor can be suspected in 50% 
of cases. 
Emotional trauma and repression have been noted to be responsible for 
very sudden onset, rapid extension and spread of lesion. Such cases are referred 
to as ‘valeceo’ type vitiligo. 
Koebner’s phenomenon is observed in 6-20% of cases of vitiligo 
vulgaris.33 Minor trauma such as scratch mark, laceration, or stitches on the 
skin results in the development of a corresponding linear depigmented macule, 
usually in 2-4 weeks. This isomorphic phenomenon indicates an abnormal 
pattern of cutaneous response to trivial physical trauma. 
A positive family history, fewer lesions, less than 5% of body surface 
area involvement, frequent segmental involvement, and greater difficulty in 
treatment but relatively better prognosis are the hallmarks of childhood 
vitiligo.34 
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Morphological variations on the typical vitiligo macule35 
1. Trichrome vitiligo refers to the presence of intermediate colour; this is a 
uniform tan coloration that is narrow to broad interface between the 
normally pigmented skin and central depigmented macule. It naturally 
evolves to a typical vitiligo macule later. 
2. Quadrichrome refers to the fourth colour; this is macular perifollicular or 
marginal hyperpigmentation seen in some cases of repigmenting vitiligo. 
3. Pentachrome vitiligo also may be observed. This includes a depigmented 
macule, tan, brown hyperpigmentation, blue-gray hyperpigmentation and 
normal pigmentation. 
4. Blue vitiligo corresponds to vitiligo macules occurring in sites of post 
inflammatory hyperpigmentation. 
5. Inflammatory vitiligo has an erythematous, raised border. 
6. Confetti macules, which are typical in colour but only 1 to 2 mm in 
diameter, may occur randomly or may be perifollicular 
Clinical Types of Vitiligo36 
1. Focal vitiligo / Vitiligo areata is an isolated macule or a few scattered 
macules: the macules are limited in both size and number. 20% of children 
with vitiligo have the focal pattern. 
2. Segmental / Dermatomal / Zosteriform Vitiligo: Segmental vitiligo is 
characterized by unilateral vitiligenous macules and patches in a 
dermatomal or quasi-dermatomal distribution. It has an earlier onset, slower 
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progression, stable course, non association with other diseases, non familial 
and it is resistant to treatment.37                
Koebnerization is absent. 5% of adults and 20% of children with vitiligo 
are found to have this pattern. 
¾ Trigeminal area involved in    > 50% of cases 
¾ Neck involvement                       23% of cases 
¾ Trunk involvement                      17% of cases 
¾ Multiple site involvement           13% of cases 
            Nearly half of these cases are associated with white hairs. 
3. Generalized vitiligo / Vitiligo vulgaris: This is the most common type of 
vitiligo and is characterized by few to many widespread macules. These 
macules are often symmetrically placed and involve extensor surfaces of the 
trunk, extremites, periorificial areas and mucous membranes. 
4. Acrofacial vitiligo involves distal digits and periorificial  facial areas. 
5. Lip – tip vitiligo: periungual involvement occurring with involvement of 
mucous membranes like lips, distal penis and nipples. 
6. Vitiligo universalis / Universal vitiligo describe such widespread vitiligo 
that there are few remaining normal macules of pigmentation; this type has 
been associated with the multiple endocrinopathy syndrome. 
7. Combination Vitiligo: very rarely vitiligo vulgaris and segmental vitiligo 
are seen in the same patient. 
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Vitiligo area scoring index38 
The percentage of vitiligo involvement is calculated in terms of hand 
units. One hand unit (which encompasses the palm plus the volar surface of all 
digits) is approximately equivalent to 1% of the total body surface area. The 
degree of pigmentation is estimated to the nearest of one of the following 
percentages: 
100% - complete depigmentation, no pigment is present; 
90% - specks of pigment present; 
75% - depigmented area exceeds the pigmented area; 
50% - pigmented and depigmented areas are equal; 
25% - pigmented area exceeds depigmented area; and 
10% - only specks of depigmentation present. 
The VASI for each body region is determined by the product of the area 
of vitiligo in hand units and the extent of depigmentation within each hand unit 
measured patch. 
 
Total Body VASI =     ∑            [hand units X residual depigmentation] 
                                All body sites 
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Vitiligo disease activity score (VIDA) 39 
The VIDA is a six-point scale for assessing vitiligo activity. Scoring is 
based on the individual’s own opinion of the present disease activity over time. 
Active vitiligo involves either expansion of existing lesions or appearance of 
new lesions. Grading is as follows: VIDA Score 
+4 – Activity of 6 weeks or less duration; 
+3 – Activity of 6 weeks to 3 months; 
+2 – Activity of 3 - 6 months; 
+1 – Activity of 6 - 12 months; 
0 - Stable for 1 year or more; and 
-1 - Stable with spontaneous repigmentation since 1 year or more. 
A low VIDA score indicates less activity. 
Depending upon the activity of the disease process vitiligo classified as 
1. Active       – V1 
2. Quiescent – V2 
3. Improving  – V3 
Depending on the etiopathogenesis vitiligo classified as40 
1. Immune       (Progressive Vitiligo) 
2. Neural         (Segmental Vitiligo) 
3. Chemical     (Contact Vitiligo) 
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Other associated cutaneous abnormalities 
1. Leucotrichia: Depigmented hairs are found commonly in isolated 
vitiligo macules, it has been reported in 9-45% of vitiligo patients. 
Presence of white hair may be a marker of poor prognosis in 
repigmentation. 
2. Premature gray hair occurs in up to 37% of patients.41 
3. Alopecia areata in 16% of cases 
4. Halo naevi42 
5. Psoriasis43 
6. Lichen planus 
7. Bullous pemphigoid 
8. Dermatitis herpetiformis44 
9. Atopic dermatitis45 
10. Ichthyosis 
11. Chronic actinic dermatitis46 
12. Twenty nail dystrophy47 
13. Connective tissue disorders: Morphoea, Lichen sclerosis, Lupus 
Erythematosus, DLE 
14. Malignant melanoma48 
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Ocular Abnormalities 
1. Iritis in 5% of patients.49,50 
2. careful examination revealed depigmentation in choroid and retina in up 
to 30% of cases.51,52 
3. Visual acuity is usually normal. 
4. Vogt-Koyanagi-harada syndrome: a rare multisystem disease 
characterized by vitiligo, poliosis, uveitis, dysacousia and alopecia. 
Otic abnormalities 
1. Sensory neural deafness has been reported in a very few patients with 
vitiligo.53 
2. Alezzandrini’s syndrome: facial vitiligo, poliosis, deafness and 
unilateral tapetoretinal degeneration. 
Systemic disease associations 
1. Thyroid abnormalities: either hypothyroidism or hyperthyroidism54 
2. Diabetes mellitus: occurs in 1 to 1.7% of vitiligo patients and 
conversely, vitiligo occurs in 4.8% of diabetic patients55, 56 
3. Addison’s disease in 2% of cases57 
4. APECED: Increase in incidence (13%) of vitiligo in patients with 
autoimmune polyendocinopathy, candidiasis, ectodermal dystrophy has 
been established. This is particularly seen in patients with extensive 
vitiligo.58 
5. Pernicious anaemia59 
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6. Hypoparathyroidism 
7. Myasthenia gravis and  Thymoma 
8. Autoimmune hemolytic anaemia 
9. Lymphomas and Leukemias 
10. HIV infection60 
11. Chronic active HCV infection 
12. Rheumatoid arthritis 
DIAGNOSIS 
1. Usually clinical 
2. Wood’s lamp examination may be required to visualize macules in fair 
skinned individuals and macules in sun protected areas. 
3. Histology. 
HISTOPATHOLOGY: 
Histopathology as a means of diagnosis is rarely employed in vitiligo 
but it useful when other cause of hypopigmentation needs to be excluded. 
The histopathological changes classically associated with vitiligo are a 
complete absence of melanocytes in the basal layer of the epidermis with loss 
of melanin content of the epidermis. The upper dermis often has sparse 
superficial perivascular infiltrate of lymphocytes with a few melanophages. 
On H& E stained sections melanocytes are recognized as randomly 
dispersed cells within the basal layer having a small rounded darkly staining 
nucleus and a clear cytoplasm as a result of shrinkage artifact. They are found 
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wedged between the basal cells of the epidermis and tend to protrude beneath 
the level of the basal cells appearing to hang down into the papillary dermis.  
Histopathology of vitiligo in sections stained with H & E61 
It varies according to the type of the lesion that is biopsied as well as the 
biopsy site. 
1. Early evolving lesion: These are inflammatory lesions, histologically 
showing sparse to moderate dense lympho-histiocytic infiltrate that is 
usually present around the superficial blood vessels as well as around 
the adnexal structures and even around dermal nerve twigs. Focal 
interface changes with vacuolization of basal cells with few 
lymphocytes in the basal cell layer close to melanocytes are also seen in 
early lesions. Melanin is slightly reduced in the basal layer but with an 
almost normal complement of melanocytes. 
2. Fully developed vitiligo of short duration: The epidermis is almost 
devoid of melanin but otherwise normal. Melanocytes are usually absent 
but an occasional melanocyte may be present. Such lesions often show 
the presence of several clear cells in the upper dermis, which have been 
identified as Langerhans cells. Inflammatory infiltrate is sparse, 
superficial and perivascular with few melanophages. 
3. Long standing lesions of vitiligo: This shows complete absence of 
melanin from the epidermis and total absence of melanocytes. The 
epidermis is flattened with loss of normal rete ridge pattern and often 
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shows hyperkeratosis. The papillary dermis shows moderate thickening 
with increased number of fibrocytes with thin elongated nuclei and 
thickened collagen. 
4. Pigmented margins of vitiligo lesion: Hyperpigmented margin may 
show increased melanin in the basal layer, increased number of 
melanocytes often with large dendrites, and large melanocytes that 
contain abundant melanin in their cytoplasm. 
5. Repigmenting vitiligo: These lesions show an epidermis that is flat and 
thin with absence of melanin and melanocytes, a testimony to the 
depigmented lesion it was. The epidermis at places shows normalization 
of its architecture with reappearance of the rete ridge pattern, presence 
of melanin in the basal cells with few melanocytes that show heavily 
melanized dentritic process. 
Special stains for melanin 
1. Fontana-Masson stain:62 Melanin is argyrophilic and use of silver stains 
indicates the presence of melanin. Argyrophilia is based on the ability of 
melanin to be impregnated with silver nitrate solution that on reduction 
with hydroquinone turns black. Melanin is also argentaffin and can 
reduce ammoniated silver nitrate in the absence of an external reducing 
agent forming black silver precipitate. 
2. The DOPA Reaction:63 This demonstrates functionally active 
melanocytes and although not of much practical importance in 
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diagnostic dermatopathology is instructive with regards to the 
biochemistry of melanization. Unfixed tissue sections of enzymatically 
separated epidermal sheets are incubated in a 0.01% of solution of 3-4 
dihydroxyphenylalanine (DOPA). This stains functionally active 
melanocytes dark brown or black. Its role in vitiligo is restricted by the 
usual absence of melanocytes in this disease. 
On the basis of DOPA reaction vitiligo may be classified as follows:64 
A.  Absolute       : No DOPA positive melanocytes 
B.   Relative type 1: Weak DOPA reaction but normal number of         
melanocytes 
C.   Relative type 2: Reduced number of DOPA positive         
                                            melanocytes 
 
Immunohistochemical staining for melanocytes: 
Immunoperoxide stains using S-100 protein and HMB 45 are used to 
identify melanocytes. 
Differential Diagnosis: 
1. Post inflammatory hypopigmentation 
2. Pityriasis alba 
3. Indeterminate Hansen’s disease 
4. Pityriasis versicolor 
5. Post kala azar dermal leishmaniasis 
6. Naevus depigmentosus 
7. Chemical leukoderma 
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8. Piebaldism 
9. Idiopathic guttate hypomelanosis 
10. Albinism 
11. Chediak-Higashi syndrome 
12. Lupus Erythematosus 
13. Ash leafy macule 
14. Waardenburg’s syndrome 
15. Woolf’s syndrome 
16. Ziprokowski-Margolis syndrome 
17. Incontinentia pigmenti 
18. Halo naevus 
19. Syphilis and Yaws. 
COURSE OF THE DISEASE 
The natural course of the disease is unpredictable and uncertain, 
most often showing tendency towards slow progression. Spontaneous 
repigmentation is noted in about 10-20% of patients, most frequently in 
sun-exposed areas and in younger patients. 
Focal vitiligo, although stable for a time, may be a precursor of 
generalized vitiligo. Spontaneous resolution is possible. The natural course 
of vitiligo vulgaris is often abrupt onset, followed by progression for a time, 
then a period of stability follows and may last for some time, even decades. 
This may be followed later by a period of rapid progression. Total 
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spontaneous regression is unusual. The most common course is one of 
gradual progression of existing macules and periodic development of newer 
lesions. 
Segmental vitiligo slowly progress for a relative period of one year 
and remains stable with little extension or regression. Tendency towards 
spontaneous pigmentation is rare. 
PROGNOSIS 
There is no reliable indicator of good prognosis, but the following 
factors usually indicate a poor prognosis: 
1. Lesions on the resistant sites, such as bony prominences, non-
fleshy areas, non-hairy areas and mucosal areas. 
2. Higher percentage of white hairs in the patch 
3. Extensive long standing cases 
4. Associated with systemic diseases 
5. Family H/O vitiligo 
6. Old age 
7. Iatrogenic factors, injudicious administration of topical and 
systemic medications. 
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MEDICAL MANAGEMENT OF VITILIGO 
The various medical therapeutic options available today are able to give 
60 -90% results either singly or in combination. 
General principles: 
1. Patient should be explained the nature of the disease and its unpredictable 
course and prognosis. 
2. Reassurance is essential. 
3. Balanced nutritious diet with good quality proteins, vitamin B complex, 
Vitamin E, and minerals such as copper, iron and zinc should be 
supplemented. 
4. Avoidance of precipitating factors and drugs like Alpha interferon,65 beta 
blockers,66 chloroquine.67 
5. Avoidance of soaps, detergents and substances containing phenolic 
compounds. 
6. Avoidance of sunlight exposure, if necessary sunscreens are prescribed. 
SYSTEMIC THERAPIES 
Photochemotherapy : 
This is the most widely employed systemic therapy for vitiligo. 
Treatment using a combination of psoralen derivatives or any other 
photosensitizing agent, orally or topically, followed by irradiation with 
Ultraviolet A constitutes photochemotherapy.68 
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Psoralens: 
Photochemotherapy using the psoralen group of drugs in conjugation 
with UVA from an artificial source is called PUVA therapy.69 When sun-
exposure is utilized as a source of UVA, it is called PUVASOL therapy.70 5-
methoxy psoralen and 8-methoxy psoralen are naturally occurring, whereas   4, 
5, 8 trimethylpsoralen is synthetic. 
Psoralens (8-MOP or TMP) are given in the dose of 0.6mg/kg/day 
followed by exposure to UVA after 1-3 hrs for 2-3 times a week. The treatment 
is started with a dose of 4J/cm2 of UVA. Subsequently increments of 0.5J/cm2 
are made till a uniform erythema occurs over the lesions or a total dose of 
8J/cm2 is reached. 
Exposure time in minutes is calculated by the formula: 
Exposure time           =                  16.7   X    Dose in J/cm2 
in minutes                                          Irradiance in W/cm2 
 
Irradiance is the amount of UVR liberated from a given source measured 
by photometers in mW/cm2. If sunlight is utilized as a source of UV light the 
TMP is preferred as it is less phototoxic when compared to 8-MOP71. If there is 
no response after 6 months or 50 treatments, PUVA should be terminated. 
Khellin 72, 73, 74, 75 
Khellin is a furanochrome used as a photosensitizer in the treatment of 
vitiligo along with UVA irradiation (KUVA).   It is administered orally at a 
dose of 100mg, two hours before UVA exposure or applied topically as a 5% 
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cream. The major advantage is that it does not induce phototoxic erythema and 
thus considered safe for home treatment or treatment with natural sunlight. 
Phenylalanine: PAUVA 76, 77, 78 
Phenylalanine has been used orally and/or topically with UVA exposure 
in treating vitiligo. A 5% aqueous solution of L-phenylalanine (50-100 mg/kg) 
was orally administered one hour before UVA radiation. Supplementation with 
10% cream 20min before exposure yielded better results. 
Other photochemotherapeutic agents: 
1. Clofazamine 
2. Griseofulvin 
3. Sulphonyl ureas and Phenothaizines have dubious value. 
Systemic corticosteroids: 
Systemic steroids are mainly used in controlling the activity of the 
disease. It can be used alone or in combination with other immunomodulators 
like levamisole or topical agents for vitiligo.  In order to reduce the side effects 
of systemic steroids it has been advocated in the pulse form, Oral Mini Pulse 
therapy (OMP) .79 
This regimen comprises of administering 5mg of betamethasone with 
breakfast on two consecutive days in a week. For children, the dosage is 0.5mg 
for every 5kg of body weight is prescribed. 
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Systemic therapy with ACTH80 (25-40 IU IM twice a week) and Oral 
prednisolone 10-40 mg/day for a period of 3months to 1 year has been tried in 
vitiligo with better results.81 
Immunomodulators: 
1. Levamisole is used alone or in combination with systemic steroids for 
control of active disease. It is useful if the patient has mild disease   (a few 
lesions which are spreading slowly).82 It is recommended in a dose of 
150mg on two consecutive days per week for a period of 16 weeks. For 
children between 6-12 years the recommended dose is 100mg and 50 mg 
for children between 3-6 years. 
2. Pentoxyphylline83 has been documented to work as an immunomodulator 
by directly acting on cytokine production. In a dose of 400mg thrice daily 
with local and or systemic steroids gave excellent results in patients unable 
to take levamisole. 
3. Isoprinosine84 in a dose of 500mg/kg for a period of six months can be tried 
as a immunomodulator. 
4. Recently a new immunomodulator, Suplatast tosilate85 is found to be 
effective in patients with vitiligo. 
5. Oral Zinc has been traditionally claimed to be effective in vitiligo. 
Nutritional agents 86, 87 
Multivitamin therapy with folic acid, Vitamin B12 and Vitamin C has 
been reported to show repigmentation, particularly in children. Antioxidants 
given for a prolonged period has a beneficial effect in vitiligo patients. 
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Other systemic agents 
Dapsone88 in a dose of 100mg/day for a prolonged period claimed to be 
useful in segmental vitiligo. It probably acts by immunomodulation. 
Nialamide, 89 a monoamine oxidase inhibitor in a dose of 150mg/day has 
been shown improvement in 50% of cases with segmental vitiligo. 
Intramuscular Injection of aqueous extract preparation of human 
placenta (Placentrex) 90 has been advocated by some to achieve good results in 
vitiligo. It is considered as a biogenous stimulator. 
Penicillamine91 has been found to repigment vitiligo in patients with 
Rheumatoid arthritis. 
Azathioprine92 in dose of 50mg/day is effective in repigmenting vitiligo 
in patients with Air Born Contact Dermatitis. 
Cyclosporine93 and cyclophospamide94 has been tried in vitiligo. 
Canthaxanthin95 a naturally occurring carotenoid, used as a food 
colouring agent and sun tanning agent, is useful in vitiligo of Type 1 and 2 skin 
as a orally effective cosmetic camouflage. 
Combination of Calcium pantothenate 100mg with Para amino 
benzoicacid (PABA) 500mg twice daily may help repigmentation of vitiligo 
patches and leukotrichia associated with vitiligo.96 
Recently a pineal gland hormone, Melatonin97 has been found effective 
in vitiligo. 
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TOPICAL THERAPIES 
Topical photochemotherapy : 
1. Topical PUVA 
Topical psoralen solutions are available as 0.75% and 1% 8-MOP and 
0.2% TMP. These are diluted in isopropyl alcohol to achieve a 0.1% solution of 
8-MOP and 0.01% of TMP. This is then applied on the lesion and exposed to 
UV radiation after 2-3 hours, initially weekly and later twice or thrice weekly.  
It can be used in patients having very few lesions and it is a safe option in 
children. An acute phototoxic reaction is an expected regular side effect. 
PUVA bath is a safer alternative to oral Psoralens. 50ml of 0.75% of 8-
MOP or 37.5ml of 1%8-MOP is added to 100 litres of water in a bathtub to 
obtain a concentration of 3.75mg/lt. The patient soaks in this solution for 15 
minutes and is then exposed to UV radiation. 
PUVA Bath suit: 98 2 ml of 0.75% or 1.5ml of 1% of 8-MOP is added to 
4 litres of water. Then a suit made up of absorbable cotton that is tailored to 
that individual is soaked in the solution, gently squeezed and the patient then 
puts it on for 15 min followed by UV exposure. 
2. Topical PAUVA:  
Topical Phenylalanine 10% cream application followed by UV exposure 
has been tried in few patients. 
3. Topical KUVA:  
Khellin 5% cream along with UVA proved to be effective in vitiligo. 
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4. Pseudocatalase: 
This treatment consisted of application of Pseudocatalase and calcium 
chloride in a cream base to the vitiligo lesions twice daily and the patients were 
subjected to short term sub-erythemogenic UVB exposure twice weekly, one 
hour after application of the cream.99 
Narrow band UVB therapy100 
Narrow band UVB therapy is presently considered a treatment of choice 
for vitiligo. It is safe in children over 6 years of age. Narrow band fluorescent 
tubes (Philips TL-01/100W) with an emission spectrum of 311 nm are used for 
this therapy. It is said to be less erythemogenic than broad band UVB. It is 
given at a starting dose of 0.075 J/cm2, biweekly, with 20% increments until 
erythema was achieved. 
Topical steroids 
Topical steroids have virtually become the first line of treatment in 
patients with a few localized lesions. Topical steroids like mometasone, 
fluticasone or prednicarbate that are less likely to produce atrophy would be 
preferred. Early lesions, facial lesions, flexural lesions, focal lesions in children 
comparatively showed better results. It may be used in combination with other 
therapies. 
Topical Tacrolimus and Topical Pimecrolimus 
Tacrolimus is a macrolide lactone produced by Streptomyces 
tsukubaensis. Tacrolimus by its immunomodulating activity found to be useful 
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in treating vitiligo. It is available as 0.03% and 0.1% ointment and it has to be  
applied twice daily for a period of 3 to 6 months, and  recent reports claimed it 
as a success even when used alone as a monotherapy.  Pimecrolimus is 
available as 1% cream. 
Topical Placentral extract101 
Human placentral extract, Placentrex lotion is an aqueous extract of 
fresh human placenta which gives clinical improvement in some cases when 
applied locally. 1 to 2 ml of the lotion depending on the size of the patch is 
rubbed gently for one minute, three times daily. Affected area was exposed to 
sunlight for 5 minutes for better results. 
Melagenina102 
Melagenina plus is a hydro alcoholic extract at 50% of human placenta 
obtained from healthy pregnant women in aseptic conditions, after normal 
deliveries. It has to be applied over the affected part once daily. Some studies 
in Cuba claimed that repigmentation occurred in 84% of cases treated with 
Melagenina. 
Basic fibroblast growth factor103 
Recent studies indicate that basic fibroblast growth factor is a putative 
growth factor for the melanocytes and is produced by keratinocyte in normal 
individuals. Recent experiments suggest that topical application of 0.5% B-
FGF gel or injection weekly or biweekly along with sunexposure show 
evidence of repigmentation both clinically and histopathologically in humans. 
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Miscellaneous topical agents 
Topical 5-Fluorouracil:104 5-FU cream has been used successfully in 
Japan for non-dermatomal vitiligo. Dermabrasion is followed by daily 
application of the cream under occlusive dressing for 7-10 days. 
Minoxidil:105 Topical Minoxidil with PUVA has been reported to 
repigment vitiligo patches better than those treated with PUVA alone. 
Minoxidil may retain the hair in the anagen phase during which the 
melanocytes are active and proliferate. 
Topical crude coal tar in combination with topical steroids when given 
to vitiligo patients showed 50% repigmentation after 10-20 weeks of therapy.106 
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SURGICAL MODALITIES FOR VITILIGO 
The various surgical procedures are designed with any of the following 
4 aims. 
1. Introduction of artificial pigments into the lesion for permanent camouflage. 
2. Removal of the depigmented areas for ever. 
3. Repopulation of the depleted Melanocytes by various grafts. 
4. Therapeutically wounding the lesion so as to stimulate the Melanocytes 
from the periphery and the normal hair follicles to proliferate, migrate and 
repigment the lesion. 
Patient selection: 
1. Patients not responding to medical line of management. 
2. Vitiligo lesions should be stable for minimum of two years. 
3. Psychologically stable patients with realistic expectations. 
Various surgical modalities include: 107 
1. Cosmetic tattooing 
2. Excision and closure 
3. Thin Thiersch’s graft 
4. Suction blister technique 
5. Miniature Punch grafting 
6. Therapeutic wounding: Dermabrasion, Laser ablation, 
      LN cryosurgery, needling, Phenol or TCA application 
7. Ultra thin grafting 
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8. Grafting of non-cultural epidermal suspension 
9. Skin cultures -- autologous, allologous or foetal: either epidermis 
containing both Melanocytes and keratinocytes (or) pure Melanocytes 
alone. 
10. Other Modalities – Trypsinized autograft injection, single hair transplant 
homologous grafting. 
Depigmenting therapy for extensive vitiligo108 
In extensive vitiligo which is refractile to the repigmenting therapies, 
bleaching or removing the remaining islands of pigments to achieve an uniform 
appearance may be cosmetically desirable. 
20% Monobenzyl ether of hydroquinone in a cream base is applied to 
the remaining areas of pigmentation twice daily for 3-6 months. It produces a 
permanent depigmentation. 
Nothing conclusive has really happened in the Medical management of 
vitiligo during the past few years. Researchers are looking for a more effective 
therapy for this common depigmentary disorder. 
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MELAGENINA PLUS LOTION 
Melagenina lotion is a hydro alcoholic extract at 50% of human placenta 
obtained from healthy pregnant women in aseptic conditions, after Cesarean 
section.109 It is used as a topical agent for repigmentation in vitiligo patients.110 
COMPOSITION OF MELAGENINA PLUS 
EACH 100 ML contain:  
50% Alcoholic extract from human placenta  -100 ml 
Calcium chloride                 -100 mg 
Phospholipids                -40 mg 
Lipids                                    -30 mg 
Proteins                                          -93 mg 
Total Cholesterol                           -20-45mg/dl 
Total nitrogen                           -10-20mg/dl 
Tests for identification of 
¾   Amino acids:            positive 
¾   LIPOPROTEIN:      positive 
¾   L-Dopa oxidation:   positive 
Calcium content:             0.2-0.5mg/ml 
Residue by evaporation: 0.004 – 0.008 g/ 100 ml 
Product dispensed in 235ml amber coloured bottles. 
  
39
MECHANISM OF ACTION 
Melagenina plus is a 50% hydroalcoholic extract of human placenta 
with the addition of calcium chloride. It is obtained from healthy pregnant 
women in aseptic conditions, after Caesarean section.    
The active principle of this extract is alpha lipoprotein with a molecular 
weight of 1500-4000 Dalton.111 
This lipoprotein stimulates the melanocytes reproduction and the 
synthesis of the melanin pigment.112 It also accelerates the oxidation of the L-
DOPA amino acid in presence of sunlight, favoring its transformation to 
melanin after internal chemical processes. 
A.Meyer Y S Nagishi (1986) described the role of calcium in the 
pigmentation process of the skin by means of stimulating the secretory activity 
of melanocytes which is related to the concentration of calcium.113, 114 
It is stated that the calcium added to this product increases the 
permeability of the cell and therefore allows a better activity of the active 
principle in the extract and an increase in number of melanocytes in the vitiligo 
lesions. 
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APPLICATION GUIDELINES 
Melagenina plus is a nontoxic biological product used as topical lotion. 
It should not be swallowed or injected. It is recommended to shake the bottle 
before using it. 
The lotion has to be applied by rubbing it with the fingertips on the 
depigmented areas, once daily, at the same time. It should remain on the skin 
for at least one hour. Exposure to sunlight or ultraviolet radiation, 30 min after 
application seems to be beneficial in large number of patients. 
It is preferable to take bath before application and it is ensured that the 
lesion is dry before application. Fans should be switched off before application. 
Cotton, gauze, towels, fabrics should not used for applying the lotion. 
Melagenina plus can be applied to any body surface. By its alcohol 
content it can produce a bit of burning or itching sensation in mucous 
membranes like lips, genital organs and perianal areas. The drug should not 
enter the eyes. 
Melagenina plus lotion should be stored in dark amber coloured bottle. 
It should be stored in a cool, dark place. There is no need of refrigeration. 
It should not be used together with other drugs like psoralens, 
corticosteroids prescribed for vitiligo, since they can equally interfere with the 
effect caused by the lotion. 
Ideally cosmetics, creams, deodorants and perfumes should not be used 
during the therapy. Bath soaps should be as neutral as possible. 
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Safety of the product:  Regarding the safety of the lotion, despite the fact 
that the Melagenina lotion has been used for more than 25 yrs, no serious 
adverse reactions have been reported. Erythema in and around the depigmented 
areas may appear during the application of the drug, which would be an 
expected adverse reaction and would not require any treatment. All placenta 
donors were screened for HIV and HBsAg infection. 
Melagenina plus is a nontoxic substance, which does not have any 
interactions with other drugs that the vitiligo patient may be using for the 
treatment of other medical problems like diabetes, hypertension and asthma  
and can be safely applied to any area in the human skin surface without any 
serious adverse effects. 
It can be safely used during menstruation, pregnancy and lactation and 
women undergoing treatment to aid conception. 
Efficacy of the product: 115 This product has an efficacy rate of 84% in 
patients suffering from vitiligo, 2yrs after initiation of therapy. 
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AIM OF THE STUDY 
The Aim of the study is to evaluate of the rate of repigmentation in  6 
months with Melagenina plus lotion and Melagenina plus lotion  along with 
UVA in the treatment of localized stable vitiligo. 
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MATERIALS AND METHODS 
Study Design: 
Melagenina plus lotion 
V/s 
Melagenina plus lotion along with Ultraviolet A irradiation 
This was a six month, randomized, open, prospective, parallel group, 
comparative study conducted in vitiligo patients attending the Vitiligo Clinic, 
Department of Dermatology, Government General Hospital, Chennai. This 
study was conducted from April 2005 to September 2006. (1 ½ years) 
Forty patients, both men and women, 13-60 years of age with clinical 
diagnosis of vitiligo were eligible for enrollment in the study. 
During the initial visit the patient’s demographic details including the 
name, age, sex, marital status, occupation, and residential address were noted.  
A detailed history regarding the onset, duration and course of the disease, 
presence or absence of precipitating factors, family history, associated skin and 
systemic problems, treatment taken so far and its outcome were recorded. 
Dermatological assessment of the disease was carried out noting down the sites 
of involvement, total body surface area involved, total number of patches, size 
and distribution of the patches, presence of white hair in the patch.  
Details regarding the margin of the patch, skin texture, presence or 
absence of perifollicular pigmentation, Koebner’s phenomenon, associated 
other skin and systemic problems were noted. Focal sepsis was ruled out by 
referring the patient to ENT and Dental OPD for check up. 
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After collecting the preliminary reports the patient was assessed for 
eligibility for randomization. Randomization was performed according to 
computer generated random code. Treatment was identified by a code number 
either A or B according to treatment group. 
Patients with code A received treatment with Melagenina plus lotion 
alone and patients with code B received treatment with Melagenina plus lotion 
along with Ultraviolet A irradiation from PUVA chamber in our department. 
The patients were asked to stick only to the study treatment as per the 
randomization code. 
Table of Randomization 
Group A Group B 
4 1 
5 2 
8 3 
9 6 
10 7 
11 12 
13 15 
14 18 
16 19 
17 20 
23 21 
27 22 
28 24 
29 25 
30 26 
31 32 
36 33 
37 34 
39 35 
40 38 
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Inclusion Criteria: 
1. Patients of both sexes. 
2. Age group between 13-60 years. 
3.  Patients suffering from vitiligo on face, trunk &   extremities. 
4. Depigmentation not more than 10% of total body surface area. 
5. Stable patches of vitiligo more than 1 year duration. 
6. Patient not on any form of therapy for vitiligo for the previous 1 month. 
Exclusion Criteria: 
1. Mucosal vitiligo, unstable vitiligo, actively spreading vitiligo. 
2. Vitiligo less than 1year duration. 
3. Vitiligo more than 10% of body surface area. 
4. Children less than 12 years of age. 
5. Pregnant and lactating women. 
6. Patient having associated systemic abnormalities (both endocrine and 
non endocrine) 
7. Patient currently under other topical or systemic therapy for vitiligo. 
8. History of photosensitivity or presence of photosensitive dermatoses. 
After fulfilling the inclusion criteria, the patients were assigned the 
study treatments. Group A patients were asked to apply Melagenina plus lotion 
topically, whereas, Group B patients were subjected to Ultraviolet A radiation 
after application of Melagenina plus lotion topically. 
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Administration of the Study Treatment 
• Melagenina plus lotion was applied (after shaking the bottle well), with 
fingertips for about 5 minutes ensuring skin is dry, once daily at the 
same time. 
• Patients were advised to have a bath before applying Melagenina plus 
lotion. 
• Patient should switch off the fan before applying Melagenina plus 
lotion. 
• Clothes should not be worn for 30 minutes after application. 
• Patients on study group B were exposed to Ultraviolet A radiation, one 
hour after application of Melagenina plus lotion, twice weekly for a 
period of 6 months. 
• The initial dose of UVA is 4joules/cm2 for a period for 6 min which    
was gradually incremented depending upon the erythema response. 
• At the time of UVA exposure patient’s eyes were protected using UVA 
blocking goggles and genitals were protected using a genital shield. 
Melagenina plus lotion is available in 235ml amber coloured bottles 
commercially. Since it is impossible in our setup to give an entire bottle to one 
patient, we used a 60 ml amber coloured glass bottles with screw cap and inner 
plastic cap to dispense the Melagenina plus lotion. We used a measuring cup 
and plastic funnel to refill the glass bottle. During the visits the patients were 
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supplied with Melagenina plus lotion, 20 or 30 ml depending upon their body 
surface area involvement. 
Total duration of study was 6 months. During the study period of 6 
months medications either local or systemic, intended for other illnesses were 
allowed to be taken.  But no other systemic medications or topical applications 
for vitiligo were allowed.  
The visits on day 3 and day 7 ensured that the patients have understood 
and were following the protocol.  This was checked during every subsequent 
visit by asking the patient about the method of application of the study 
medication.  This ensured the compliance of the protocol. 
Subsequently the patients were followed up once in two weeks for a 
total period of 6 months and once a month during the next 3 months to watch 
for any clinical relapse after using the medication for 6 months. 
If the patient was on any other form of topical therapy for vitiligo, 
before commencing the study a wash out period of one month was given before 
prescribing the Melagenina plus lotion. 
Any adverse effects during the study were recorded with importance to 
erythema and systemic side effects. If any adverse effects are observed then its 
severity, onset, course, action taken and relationship to study drug were 
recorded. 
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EFFICACY PARAMETERS 
The primary efficacy variable was the percentage change in 
depigmentation from baseline to the end of study period. (i.e. 6 months) 
The secondary efficacy parameters include the Physician’s Global 
Improvement assessment and Patient’s Global Assessment which was 
computed at the end of 6 months of the study. 
During the initial assessment, estimation of body surface area (BSA) 
involvement was assessed using Vitiligo Area Scoring Index (VASI). The body 
was divided into five separate and mutually exclusive regions: Face and Neck, 
Upper extremities (excluding Hands), Lower extremities (excluding Feet), 
Hands and Feet and Trunk. Buttocks were included with the lower extremities. 
One hand unit, which encompasses the palm plus the volar surface of all 
the digits is approximately 1% of total body surface area and was used as a 
guide to estimate the baseline percentage of vitiligo involvement of any body 
region. To eliminate variation in hand size, we defined a hand unit to be the 
volar hand, including the fingers of single investigator. 
All the patients were followed up once in every two weeks, to look for 
any macular repigmentation and presence of adverse effects. At each follow up 
assessment the extent of residual depigmentation within each affected patch 
that had been present at baseline was estimated to the nearest of one of the 
following percentages: 0, 10%, 25%, 50%, 75%, 90%, or 100%. Any new 
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depigmented patches that developed during the study were also estimated using 
the hand unit method and were included in the VASI calculation. 
For each body region the VASI was determined by the product of the 
area of vitiligo in hand units (which were set at 1% per unit) and the extent of 
depigmentation within each hand unit measured patch. 
Standardized assessment for estimating the degree of pigmentation to 
derive the VITILIGO AREA SCORING INDEX (VASI). 
At 100% depigmentation, No pigment is present. 
At 90%, specks of pigment are present. 
At 75%, the depigmented area exceeds the pigmented area. 
At 50%, the depigmented area and the pigmented area are equal. 
At 25%, the pigmented areas exceed the depigmented area 
At 10%, only specks of depigmentation are present. 
Total body VASI was then calculated using the following formula by 
considering the contributions of all body regions (possible 0-100) 
Total Body VASI =     ∑         [hand units X residual depigmentation]                
                                All body sites 
 
Clinical photographs were taken at baseline and at each monthly follow 
up visits as an aid to the Global clinical scoring. They were not used to derive 
the VASI, which was instead determined by direct clinical examination. 
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The Physician’s Global improvement assessment evaluated the overall 
change from baseline in VASI score on a 5 point scale. 
Score Improvement in % Comments 
1 76%-100% Excellent improvement 
2 51%-75% Marked improvement 
3 26%-50% Definite improvement 
4 1%  -25% Minimal improvement 
5 0% No change 
 
Patient’s Global assessment was evaluated based on the response to the 
treatment as perceived by the patient with or without comparison to previous 
treatment if any. This was assessed in a 4 point scale. 
 
          Primary efficacy parameter, VASI was assessed at baseline and then 
once in a month during follow up for 9 months and Secondary efficacy 
parameters Physician’s Global assessment and Patient’s Global assessment 
were evaluated only at the end of 6 months. 
The investigator performed all the efficacy evaluation except the 
patient’s Global assessment. 
Score  
1 Much better 
2 Slightly better 
3 Same 
4 Worse 
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STATISTICAL ANALYSIS 
It was calculated that a sample size of 20 patients per group would 
provide 90% power to detect a 40% difference between treatments, assuming a 
common standard deviation of 40%. 
Efficacy Analysis included all randomized patients either in Group A or 
Group B who completed the study period of 6 months. 
Safety Analysis included all randomized patients who applied the 
medication at least once during the study period, irrespective of whether they 
completed the study or not. 
The primary efficacy criterion was the reduction in percentage of 
depigmentation from the baseline as evaluated using VASI scoring. 
Between groups comparison of the primary efficacy criterion was 
performed using analysis of covariance (ANCOVA) with the VASI score at 
baseline as Covariate. P-values less than 0.05 were considered significant. 
Between groups comparisons for secondary variables were evaluated 
using the analysis of variance (ANOVA). The change from baseline of efficacy 
parameters within each treatment group was evaluated using the student t-test. 
Descriptive statistics were used to evaluate baseline characteristics and 
adverse effects. 
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OBSERVATION 
A total of 40 patients were enrolled in the study, with 20 patients 
randomized to receive treatment with Melagenina plus lotion and 20 patients to 
receive treatment with Melagenina plus lotion and Ultraviolet A irradiation 
(MUVA). All 40 patients were included in the safety population. 
 
 Melagenina MUVA 
 Male Female Total Male Female Total 
Total enrolled 10 10 20 8 12 20 
Completed 10 9 19 6 10 16 
Drop out 0 1 1 2 2 4 
 
Out of these 40 patients, 35 patients completed the study for the period 
of 6 months. Five of these patients, 1 (5%) in the Melagenina group and 4 
(20%) in the MUVA group, discontinued the study and their efficacy data was 
not included in the analysis. The higher percentage of patient dropouts in 
MUVA group is probably due to inability of the patients to come twice weekly 
for a period of 6 months. None of the drop outs are due to adverse effects. Most 
of the drop outs are between 4 to 12 weeks after commencing the treatment 
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Age and Sex distribution: 
 
Melagenina plus  Melagenina plus + UVA 
Age Male Female Total  Age Male Female Total 
13-20 yrs 4 3 7  13-20 yrs 1 3 4 
21-30 yrs 3 5 8  21-30 yrs 4 6 10 
31-40 yrs 2 1 3  31-40 yrs 3 3 6 
41-50 yrs 0 1 1  41-50 yrs 0 0 0 
51-60 yrs 1 0 1  51-60 yrs 0 0 0 
 10 10 20   8 12 20 
 
Out of the 20 patients enrolled for group A treatment plan (M), 10 were 
Males and other 10 were Females. 40% of them are in the age group of 21 to 30 
yrs. Out of the 20 patients enrolled for group B treatment plan (MUVA), 8 
were Males and 12 were Females, predominantly in the age group of 21 to 30 
yrs (50%).  
The mean age of patients in group A was 26.6 yrs and in group B it was 
also 26.6 yrs. 
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Disease duration in years: 
 Melagenina Melagenina + UVA 
Total in years 2.6375 yrs (n=20) 2.0000 yrs (n=20) 
Male 2.7000 yrs (n=10) 1.3750 yrs (n= 8) 
Female 2.5750 yrs (n=10) 2.4200 yrs (n=12) 
 
The mean duration of vitiligo was 2.64 yrs in patients enrolled for 
Melagenina group and 2.00 yrs in the MUVA group. 
 
Type of vitiligo: 
 Melagenina Melagenina + UVA 
 Male Female Total Male Female Total 
Segmental 3 0 3 0 0 0 
V.Vulgaris 0 3 3 8 8 16 
Acral 3 1 4 0 1 1 
Focal 4 6 10 0 3 3 
 10 10 20 8 12 20 
 
10 patients with focal vitiligo, 3 with segmental vitiligo, 3 with vitiligo 
vulgaris and 4 with acral vitiligo were included in Melagenina in treatment 
group. 16 patients with vitiligo vulgaris, 3 with focal vitiligo and 1 with acral 
vitiligo were included in the MUVA group.  
Patients with mucosal involvement alone were not included in the study. 
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Total body VASI reduction: 
 
Total body 
VASI 
0 mon 2 mon 4 mon 6 mon 
M 
0.9976 
(100%) 
0.9763 
(97.86%) 
0.8668 
(86.90%) 
0.7793 
(78.12%) 
MUVA 
2.3356 
(100%) 
2.1781 
(93.26%) 
1.9203 
(82.22%) 
1.5281 
(65.43%) 
 
             The mean total body VASI in Melagenina group at baseline was 
0.9976 (Taken as 100%) and in MUVA group it was 2.3356(100%) with a  
P value 0.005.  
 The mean total body VASI at the end of 2 months in Melagenina group 
was 0.9763 (97.86%) and in MUVA group was 2.1781 (93.26%). It shows that 
VASI reduction was earlier in patients belonging to MUVA group. 
After the end of 6 months the mean total body VASI in Melagenina 
group was 0.7793 (78.12%) and in MUVA group was 1.5281 (65.43%) with a  
P value 0.02. The P value was statistically significant.  
The total body VASI reduction in percentage after 6 months of therapy 
with Melagenina alone was 21.88% and 34.57% in MUVA group. 
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Area wise VASI 
reduction 
Face& 
neck 
Upper 
limb 
Lower 
limb 
Hands& 
Feet 
Trunk 
MELAGENINA      
0 mon 100   % 100    % 100   % 100   % 100   % 
2 mon 98.23 % 88.38 % 98.70 % 100   % 100   % 
4 mon 90.40 % 63.76 % 85.55 % 100   % 83.33 % 
6 mon 86.11 % 48.61 % 68.89 % 90.58 % 55.56 % 
MUVA      
0 mon 100  % 100    % 100   % 100 % 100   % 
2 mon 96.97 % 85.56 % 91.70 % 100 % 92.50 % 
4 mon 71.21 % 85.56 % 83.54 % 100 % 71.25 % 
6 mon 40.91 % 61.50 % 67.44 % 100 % 50.62 % 
The area wise VASI reduction in Melagenina group is as follows:- 
Upper limb 51.39%, Trunk 44.44%, Lower limb 31.11%, Face & Neck 
13.89% and Hand & Feet 9.42%. 
The area wise VASI reduction in MUVA groups is as follows:- 
Face & Neck 59.09%, Trunk 49.38%, Upper limb 38.50%, Lower limb 
32.56% and Hands & Feet 0%. 
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The VASI reduction in vitiligo types of Melagenina group was noted as 
follows: - segmental vitiligo 48.38%, focal vitiligo 38.78%, vitiligo vulgaris 
8.89% and acral vitiligo 9.42%.  
The VASI reduction in vitiligo types of MUVA group was as follows: - 
focal vitiligo 43.55%, vitiligo vulgaris 34.24% and acral vitiligo 0%. 
 
 
 
The overall efficacy of Melagenina alone was 33.74% and MUVA was 
37.01% after the end of 6 months. 
 
 
 
 
VASI reduction 
in vitiligo types 
V.Vulgaris Focal Segmental Acral 
MELAGENINA     
0 mon 100 % 100 % 100 % 100 % 
2 mon 100 % 94.46 % 94.24 % 100 % 
4 mon 96.67 % 72.80 % 66.03 % 100 % 
6 mon 91.11 % 61.22 % 51.62 % 90.58 % 
MUVA     
0 mon 100 % 100 % 0 100 % 
2 mon 92.55 % 96.77 % 0 100 % 
4 mon 82.18 % 79.03 % 0 100 % 
6 mon 65.76 % 56.45 % 0 100 % 
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Total reduction in VASI: Physician’s Global assessment: 
 
 Melagenina MUVA 
Score   No of 
Patients
(%) No of 
Patients 
(%) 
5 No change 0% 4 21.05% 3 18.75% 
4 Minimal 
improvement 
1% -  25% 6 31.58% 4 25.00% 
3 Definite 
improvement 
26%-50% 5 26.31% 6 37.50% 
2 Marked 
improvement 
51%-75% 2 10.53% 2 12.50% 
1 Excellent 
improvement 
76%-100% 1 10.53% 1 06.25% 
       
  The mean physician’s global assessment score was 3.421 in 
Melagenina group and it was 3.375 in MUVA group (P value 0.911). 
Physician’s global assessment clearly showed that only 26.31% of patients 
treated with Melagenina alone had definite improvement whereas 37.50% of 
patients treated by MUVA had definite improvement.  
The mean of patient’s global assessment in Melagenina group was 2.69 
and in MUVA group it was 2.53 (P value 0.66).The P value in both assessment 
was statistically insignificant. 
No serious cutaneous or systemic adverse effects were noted in the 
study. 1 patient (5%) in the Melagenina group and 3 patients (15%) in MUVA 
group developed erythema which did not warrant discontinuation of therapy. 
  
59
94.44ml of Melagenina plus lotion per body surface area was utilized by 
patients in Melagenina study group and 91.46 ml per body surface area was 
utilized by patients in MUVA group.  
This roughly works out to 1 bottle for 6 months in a patient with 2.5% of 
body surface area involvement of vitiligo. 
The average cumulative joules per patient is 171.5 j/cm2 in patients 
received UVA along with Melagenina plus lotion. 
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DISCUSSSION 
This clinical comparative trial explored the efficacy of Melagenina plus 
lotion when used alone in comparison with Melagenina plus lotion with 
Ultraviolet A irradiation in patients suffering from vitiligo less than 10% of 
body surface area involvement. 
This is a unique study in that it was the first of its kind in INDIA. 
The baseline demographic data and baseline characteristics in both study 
groups, when compared were similar. The total number of patients with vitiligo 
vulgaris is more in MUVA group is probably due to the higher number of 
patients consented for undergoing Ultraviolet therapy. The overall efficacy of 
MUVA is slightly greater than Melagenina plus lotion alone after the end of 6 
months. This shows that Melagenina alone can be effectively used as topical 
monotherapy in patients with localized stable vitiligo. 
However patients in MUVA group showed significant reduction in total 
body VASI score in 2 months when compared to Melagenina plus lotion alone. 
The reduction in MUVA group is 6.74% when compared to 2.14% in 
Melagenina group in the first two months of study period. This clearly shows 
that significant repigmentation occurs earlier in patients treated with MUVA. 
Patients with focal vitiligo and segmental vitiligo showed better clinical 
response to Melagenina plus lotion, when compared to vitiligo vulgaris. The 
clinical response to Acral Vitiligo was very poor.  
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Vitiligo affecting the sun exposed area of the body showed better 
response to MUVA, when compared to Melagenina plus lotion alone. 
The secondary efficacy parameters like Physician’s Global Assessment 
and the Patient’s Global Assessment shows results slightly in favour of MUVA 
group. 
Apart from transient erythema, no serious adverse effects were noted. 
There was no increase in pigmentation of surrounding normal skin, which 
shows that Melagenina has no effect on normal skin. 
During the follow up period of three months after completion of the 
study, none of the patients in both study groups showed clinical signs of relapse 
evidenced by the fact that VASI remains the same as that of 6 months. This 
shows that pigmentation achieved by Melagenina plus lotion may be 
permanent. 
If Melagenina plus lotion is continued for a prolonged time there is 
greater chance of achieving complete repigmentation of vitiligo. 
Small sample size, lack of placebo control and shorter duration of study 
were the major pitfalls in this study. 
Nevertheless Melagenina plus lotion when used alone or in combination 
with Ultraviolet radiation there was a definite improvement in repigmentation 
of localized stable vitiligo. 
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CONCLUSION 
 
1. Melagenina plus lotion can be effectively used as topical monotherapy 
for treating localized stable Vitiligo. When used alone its overall 
efficacy is 33.74% after a period of 6 months. 
 
2. When Ultraviolet A radiation was combined with Melagenina plus 
lotion (MUVA) there was significant reduction in VASI score at an 
earlier date, when compared to Melagenina plus lotion monotherapy. 
 
3. The overall efficacy of MUVA is 37.01%, which was only slightly 
higher than Melagenina plus lotion monotherapy. 
 
4. Localized Vitiligo in sun exposed areas like face and upper limbs 
showed better response to MUVA. 
 
5. Melagenina plus lotion was most effective in focal and segmental 
Vitiligo than in Vitiligo vulgaris. 
 
6. Melagenina plus lotion was safe as there were no serious systemic or 
cutaneous adverse effects apart from transient erythema in a few 
patients. 
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    PROFORMA     
         
       Serial NO             : 
         
Name of the patient               :    O.P./I.P. NO        : 
         
Name of the Parent / Guardian  :    Date of enrollment : 
         
Age                                       :   yrs     
         
Sex                                       :   Male   Female   
         
Occupation                            :        
         
Marital Status                        :   Single   Married   
         
Residential Address               :       
         
    HISTORY     
         
H/O Presenting Compliants :      
         
Duration of illness        
   days   weeks   months   years 
         
H/O Itching       yes   no   
         
H/O drug intake before the onset      
 of skin lesions   yes    no   
         
H/O external application   yes    no    details 
         
H/O contact with chemicals   yes    no    details 
         
H/o Photosensitivity    yes    no    
         
H/o Physical and emotional        
 stress    yes    no    
         
H/O trauma    yes    no    
         
H/O GIT disturbances   yes    no    
         
Family History    present   absent   
         
H/O other systemic problems         
PAST HISTORY        
         
    Diabetes mellitus                        Hypertension           CAD   
         
         TB             Epilepsy      Asthma   
                   
PERSONAL HISTORY       
         
H/O exposure to STD   present   absent   
Smoker   alcoholic        
         
Veg   Non Veg        
         
Menstrual History          
         
Treatment details           
         
GENERAL EXAMINATION       
         
   DERMATOLOGIC ASSESSMENT   
1. Site of involvement        
         Face & Neck       Upper extremities     
         Trunk       Lower extremities     
         Hands & Feet        
2. Total Body surface involvement in percentage       
         
3. Total number of patches        
         
4. Size of the patches          X   cms  
         
5. Presence of white hairs in the patch   yes   no  
        
6. Texture of the Skin    normal   abnormal
        
7. Margin of the patch   Hyperpigmented   Trichrome   
    inflammatory   Quadrichrome  
        
8. Presence of perifollicular pigmentation   yes   no  
9. Koebner's phenomenon    yes   no  
10. Associated skin disease if any        
         
11. Associated systemic disorders if any       
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5. Presence of white hairs in the patch   yes   no  
        
6. Texture of the Skin    normal   abnormal
        
7. Margin of the patch   Hyperpigmented   Trichrome   
    inflammatory   Quadrichrome  
        
8. Presence of perifollicular pigmentation   yes   no  
9. Koebner's phenomenon    yes   no  
10. Associated skin disease if any        
         
11. Associated systemic disorders if any       
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patch 
       
No of patches        
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Perifollicular 
repigmentation 
       
Pigmentation 
over margins 
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pigmentation 
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patch 
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Physician’s Global Evaluation 
 VISIT II  
2 weeks 
VISIT III 
4 weeks 
VISIT IV 
6 weeks 
VISIT V 
8 weeks 
VISIT VI 
10 
weeks 
VISIT VII 
12 
weeks  
 
   Grade 
 
      
 
 VISIT VIII 
14 weeks  
VISIT IX
16 
weeks 
VISIT X 
18 
weeks 
VISIT XI 
20 
weeks 
VISIT XII 
22 
weeks 
VISIT XII 
24 
weeks 
 
    Grade 
 
      
 
 
 
 
 
 
 
Grade Improvement in % comments 
1 76%-100% Excellent improvement 
2 51%-75% Marked improvement 
3 26%-50% Definite improvement 
4 1%  -25% Minimal improvement 
5 0% No change 
                                
 Patient’s Global Evaluation  
 
 VISIT II 
2 weeks 
VISIT III 
4 weeks 
VISIT IV 
6 weeks 
VISIT V 
8 weeks 
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14 weeks 
VISIT IX 
16 
weeks 
VISIT X 
18 weeks 
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20 weeks 
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22 weeks 
VISIT XIII 
24 weeks 
 
    Grade 
 
      
 
Grade  
1 Much better 
2 Slightly better 
3 Same 
4 Worse 
     
Adverse Events 
Adverse 
Event  
Severity Onset Course Action Relationship to 
study drug 
 
 
     
 
 
     
 
 
     
 
